Author:
Khurana Alkesh,Dhingra Bhavna
Publisher
Springer Nature Singapore
Reference32 articles.
1. Draft updated IAP RNTCP Ped TB guidelines. 2019. Central TB Division MOHFW New Delhi, India; p 21.
2. Sharma SK, Ryan H, Khaparde S, Sachdeva KS, Singh AD, Mohan A, Sarin R, Paramasivan CN, Kumar P, Nischal N, Khatiwada S, Garner P, Tharyan P. Index-TB guidelines: guidelines on extrapulmonary tuberculosis for India. Indian J Med Res. 2017;145(4):448–63. PMID: 28862176; PMCID: PMC5663158. https://doi.org/10.4103/ijmr.IJMR_1950_16.
3. Centers for Disease Control and Prevention (CDC). Tuberculosis associated with blocking agents against tumor necrosis factor-alpha--California, 2002–2003. MMWR Morb Mortal Wkly Rep. 2004;53(30):683–6.
4. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098–104. https://doi.org/10.1056/NEJMoa011110.
5. Okur E, Yilmaz A, Saygi A, Selvi A, Süngün F, Oztürk E, Dabak G. Patterns of delays in diagnosis amongst patients with smear-positive pulmonary tuberculosis at a teaching hospital in Turkey. Clin Microbiol Infect. 2006;12(1):90–2. https://doi.org/10.1111/j.1469-0691.2005.01302.x.